Here is the thing almost every comparison of these three gets wrong. Two of them are edits of the same 1982 molecule. The third is an impostor that hits a different receptor entirely. Lump all three together as “growth hormone peptides” and you will design a study that can’t tell them apart.
We will sort them by receptor, because that is the line that actually matters. First, though, where the parent molecule came from.
One hormone, two edits, one impostor
Back in 1982, Guillemin’s group isolated a 44-amino-acid peptide from a human pancreatic tumor sample. In the reported in vitro assays, the synthetic copy triggered growth hormone release, matching the activity of the isolated peptide [1]. That peptide is GHRH, also written GRF. Its sequence opens Tyr-Ala-Asp-Ala-Ile-Phe, and that first tyrosine is central to the structural comparisons below.
Sermorelin and tesamorelin are both carved from GHRH. Ipamorelin is not. Keep that split in your head.
Sermorelin: the shortest working fragment
You do not need all 44 residues. The first 29, capped with an amide, keep the activity. That fragment, GRF(1-29)NH2, is sermorelin, and it serves as the native reference peptide in GHRH analogue work [2]. Everything past residue 29 can go, which is why the fragment, not the full peptide, became the yardstick.
Plasma stability is another part of the comparison. Frohman’s lab studied human GHRH(1-44) in human plasma in vitro using HPLC. The reported half-life was 17 minutes, and the main degradation fragment retained less than 0.1% of the original activity [3]. Those measurements describe GHRH(1-44), not a direct half-life measurement for sermorelin. A sermorelin assay needs its own stability measurements rather than an assumed value from the longer peptide.
What chews it up got a name in 1989. Dipeptidylpeptidase IV, DPP-IV, snips off the first two residues, and a D-amino acid at position 1 or 2 stops the snip cold [4]. Remember that, because the next compound was built around exactly this problem.
Tesamorelin: the same backbone, with a guard
Tesamorelin is GHRH with one tweak. Its development name was TH9507, and the change is a trans-3-hexenoyl group bolted onto the tyrosine at position 1. That single addition made it resistant to DPP-IV [5].
The study also examined stability and elimination. The modification slowed degradation in rat, dog and human plasma in vitro. In dogs, the apparent elimination half-life was 21 to 45 minutes [5]. Sermorelin and tesamorelin share a receptor, but they are not identical-backbone controls. Sermorelin contains 29 residues, while tesamorelin retains the 44-residue GHRH sequence with an N-terminal modification. Both sequence length and the terminal modification matter when interpreting a stability comparison.
Ipamorelin: a different receptor altogether
Ipamorelin never touches the GHRH receptor. It is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, and it binds GHS-R1a, the growth hormone secretagogue receptor most people now call the ghrelin receptor [6].
So the comparison is lopsided, and in a useful way. Set sermorelin or tesamorelin next to ipamorelin and you are running two receptor systems, not three flavors of one.
Raun and colleagues measured growth hormone release in rat pituitary cells. Ipamorelin and GHRP-6 had EC50 values of 1.3 and 2.2 nmol/L, respectively. In swine, the investigators also measured ACTH and cortisol responses, which did not exceed those observed with GHRH under the tested conditions [6]. These observations describe the rat-cell assay and swine model, not a general endocrine profile.
Side by side
| Sermorelin | Tesamorelin | Ipamorelin | |
|---|---|---|---|
| Based on | GHRH(1-29) | GHRH(1-44), modified | None (ghrelin-receptor ligand) |
| Receptor | GHRH receptor | GHRH receptor | GHS-R1a |
| Key design feature | Shortest active GHRH fragment | trans-3-hexenoyl on Tyr1, DPP-IV resistant | Pentapeptide, GHS-R1a agonist |
| Plasma stability note | DPP-IV sensitive, like native GHRH | Half-life 21 to 45 min in dogs [5] | In swine, ACTH and cortisol responses did not exceed those observed with GHRH [6] |
How to design the comparison
A few things fall straight out of the biology. Comparing sermorelin against tesamorelin? The real variable is DPP-IV resistance, so the difference lives in a plasma-stability assay, not a single-timepoint snapshot that papers over it. Adding ipamorelin? You have crossed to another receptor, so a GHS-R antagonist control earns its spot on the plate.
For an in vitro comparison, test each receptor system with its own controls. Separate readouts help distinguish GHRH-receptor signaling from GHS-R1a signaling.
For one of these on its own, see our tesamorelin GHRH analogue overview. Our sermorelin vs ipamorelin analysis digs into that two-way split.
References
- Guillemin R, et al. Science. 1982;218(4572):585-587. PubMed 6812220
- Dubreuil P, et al. Growth Horm IGF Res. 2001;11(3):173-186. PubMed 11735232
- Frohman LA, et al. J Clin Invest. 1986;78(4):906-913. PubMed 3093533
- Frohman LA, et al. J Clin Invest. 1989;83(5):1533-1540. PubMed 2565342
- Ferdinandi ES, et al. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611
- Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. PubMed 9849822
Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.
This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.
